Anti-osteoporosis drugs market being heated

Published: 2003-05-29 06:59:00

Updated: 2003-05-29 06:59:00

Business sources say that with the new launching of Handok Pharm's Actonel (risedronate), the domestic anti-osteoporosis drugs market has emerged as an arena of fierce competition among several pharmaceutical makers.

Handok Pharm expects to achieve 3.0 billion won in sales this year and plans...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK